Meta‐analysis: the significance of screening for JAK2V617F mutation in Budd–Chiari syndrome and portal venous system thrombosis

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Alimentary Pharmacology and Therapeutics

• Publication date

  2011-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2036.2011.04627.xPMID 21395632
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• JAK2V617F mutation and myeloproliferative disorders in splanchnic vein thrombosis

  2011cited by this paper
• JAK2V617F mutation and myeloproliferative disorders in splanchnic vein thrombosis: authors’ reply

  2011cited by this paper
• Splanchnic vein thrombosis: clinical presentation, risk factors and treatment

  2010cited by this paper
• Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

  2010cited by this paper
• Acute portal vein thrombosis unrelated to cirrhosis: A prospective multicenter follow‐up study

  2010cited by this paper
• Budd Chiari syndrome and V617F/JAK 2 mutation linked with the myeloproliferative disorders.

  2010cited by this paper
• Prevalence of the JAK2 V617F and MPL Mutations in Stroke, Abdominal and Peripheral Venous Thrombosis

  2010cited by this paper
• JAK2 mutations across a spectrum of venous thrombosis cases.

  2010cited by this paper
• JAK2V617F Mutation in Patients with Splanchnic Vein Thrombosis

  2010cited by this paper
• The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto‐splenomesenteric venous thrombosis

  2010cited by this paper
• JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis.

  2009cited by this paper
• Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study

  2009cited by this paper
• Vascular disorders of the liver

  2009cited by this paper
• Etiology, management, and outcome of the Budd-Chiari syndrome.

  2009cited by this paper
• Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development.

  2009cited by this paper
• JAK2V617F Mutation in Patients with Portal Vein Thrombosis

  2008cited by this paper
• Venous thrombosis in oral contraceptive users and the presence of the JAK2 V617F mutation

  2008cited by this paper
• Occurrence of the JAK2 V617F mutation in the Budd–Chiari syndrome

  2008cited by this paper
• Janus kinase-2 mutation, cirrhosis and splanchnic vein thrombosis.

  2008cited by this paper
• Primary thrombophilia in México VII: the V617F mutation of JAK2 is not a frequent cause of thrombosis

  2008cited by this paper
• The JAK2V617F tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis

  2008cited by this paper
• JAK2 V617F mutation is not involved in thromboembolism in IBD.

  2008cited by this paper
• JAK2V617F: better diagnostic tool than marrow?

  2008cited by this paper
• The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases.

  2008cited by this paper
• Clinical JAK2V617F mutation testing: Limited utility for general hospital patients with venous and arterial thromboses in common locations

  2008cited by this paper
• JAK2 V617F mutation in patients with catastrophic intra-abdominal thromboses.

  2007cited by this paper
• Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders

  2007cited by this paper
• The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis

  2007cited by this paper
• JAK2V617F in idiopathic venous thromboembolism occurring in the absence of inherited or acquired thrombophilia

  2007cited by this paper
• Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings

  2007cited by this paper
• JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis

  2007cited by this paper
• High prevalence of the JAK2 V617F mutation in patients with extrahepatic portal vein thrombosis

  2007cited by this paper
• Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl.

  2006cited by this paper
• Abdominal vein thrombosis in essential thrombocythemia: prevalence, clinical correlates, and prognostic implications

  2006cited by this paper
• Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management.

  2006cited by this paper
• JAK2 mutation: The best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis?

  2006cited by this paper
• Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis.

  2006cited by this paper
• Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome.

  2006cited by this paper
• Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis

  2006cited by this paper
• Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

  2005cited by this paper
• Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.

  2005cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

  2005cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

  2005cited by this paper
• A gain-of-function mutation of JAK2 in myeloproliferative disorders.

  2005cited by this paper
• Bone marrow histopathology in myeloproliferative disorders--current diagnostic approach.

  2005cited by this paper
• Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis

  2005cited by this paper
• Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

  2005cited by this paper
• Hepatic venous outflow tract obstruction etiopathogenesis: Asia versus the West

  2004cited by this paper
• Consensus Statement

  2004cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.

  2000cited by this paper
• Spontaneous Erythroid Colony Formation as the Clue to an Underlying Myeloproliferative Disorder in Patients with Budd-Chiari Syndrome or Portal Vein Thrombosis

  1997cited by this paper
• Bias in meta-analysis detected by a simple, graphical test

  1997cited by this paper
• Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders.

  1988cited by this paper
• Meta-analysis in clinical trials.

  1986influential reference
• Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome.

  1985cited by this paper

• The Yin and the Yang of Hemostasis in End-Stage Liver Disease

  2023cites this paper
• Differentiation between small hepatocellular carcinoma (<3 cm) and benign hepatocellular lesions in patients with Budd-Chiari syndrome: the role of multiparametric MR imaging

  2023cites this paper
• Evaluation of outcome from endovascular therapy for Budd-Chiari syndrome: a systematic review and meta-analysis

  2022cites this paper
• Portal Vein Recanalization and Transjugular Intrahepatic Portosystemic Shunt Creation and the Management of Portal Vein Thrombosis

  2022cites this paper
• The Edge of Unknown: Postoperative Critical Care in Liver Transplantation

  2022cites this paper
• Molecular Genetics of Thrombotic Myeloproliferative Neoplasms: Implications in Precision Oncology

  2021cites this paper
• Budd-Chiari Syndrom, Review und Illustration der Bildgebung

  2021cites this paper
• Report : A case of PAI-1 4 G / 5 G heterozygosity causing Budd-Chiari Syndrome [ version 2 ; peer review : 1 approved with reservations , 1 not approved ]

  2020cites this paper
• Paraneoplastic Thromboembolism and Thrombophilia: Significance in Visceral Medicine

  2020cites this paper
• An Update on the Management of Budd–Chiari Syndrome

  2020cites this paper
• Cerebral and Splanchnic Vein Thrombosis: Advances, Challenges, and Unanswered Questions

  2020influential citation
• JAK2V617F mutation prevalence on Chilean adults suffering from primary mesenteric and portal venous thromboses

  2020cites this paper
• Review article: a multidisciplinary approach to the diagnosis and management of Budd‐Chiari syndrome

  2019cites this paper
• Budd–Chiari Syndrome and Myeloproliferative Neoplasms

  2019cites this paper
• Prevalence of prothrombotic factors in patients with Budd–Chiari syndrome or non‐cirrhotic nonmalignant portal vein thrombosis: A hospital‐based observational study

  2019cites this paper
• Extrahepatic Portal Vein Obstruction: Asian and Global Perspective

  2018cites this paper
• Diagnostic Methods for Cirrhosis and Portal Hypertension

  2018cites this paper
• Hypercoagulability in End-stage Liver Disease: Review of Epidemiology, Etiology, and Management

  2018cites this paper
• Budd–Chiari syndrome/hepatic venous outflow tract obstruction

  2018cites this paper
• Prevalence of CALR mutations in splanchnic vein thrombosis: A systematic review and meta-analysis.

  2018cites this paper
• Vascular diseases of the liver. Clinical Guidelines from the Catalan Society of Digestology and the Spanish Association for the Study of the Liver.

  2017cites this paper
• Budd-Chiari Syndrome in a Patient with JAK-2 Mutation without Myeloprolifrative Disorder

  2017influential citation
• Identification of differentially expressed genes in Budd-Chiari syndrome by RNA-sequencing

  2017cites this paper
• Occult myeloproliferative neoplasms: not so occult any more

  2017cites this paper
• Vascular diseases of the liver. Clinical Guidelines from the Catalan Society of Digestology and the Spanish Association for the Study of the Liver.

  2017cites this paper
• Long‐term outcomes following percutaneous hepatic vein recanalization for Budd–Chiari syndrome

  2017cites this paper
• Sport-Related Portal Vein Thrombosis: An Unusual Complication

  2017cites this paper
• Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial

  2017cites this paper
• Portal vein thrombosis – a primer for the general physician

  2017cites this paper
• Risk and Prognostic Factors in Cerebral Venous Thrombosis

  2017cites this paper
• Review article: the aetiology of primary Budd–Chiari syndrome – differences between the West and China

  2016cites this paper
• Increased prevalence of heparin-induced thrombocytopenia in patients with Budd–Chiari syndrome: a retrospective analysis

  2016cites this paper
• Clinical Study of Selective Pericardial Devascularization on the Formation of Portal Venous Thrombosis in Portal Hypertension Patients

  2016cites this paper
• Budd-Chiari syndrome: current perspectives and controversies.

  2016cites this paper
• Budd-Chiari Syndrome/Hepatic Venous Outflow Tract Obstruction: East vs West

  2016cites this paper
• Myeloproliferative Syndromes and Thrombocythemia

  2016cites this paper
• Portal cavernoma in a case of alcoholic liver disease with myeloproliferative neoplasm

  2016cites this paper
• Benefit Stratification of Prophylactic Anticoagulation in Liver Cirrhosis: More Questions Than Answers.

  2015cites this paper
• Prevalence of Budd-Chiari Syndrome during Pregnancy or Puerperium: A Systematic Review and Meta-Analysis

  2015cites this paper
• Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment

  2015cites this paper
• Association between JAK2 rs4495487 Polymorphism and Risk of Budd-Chiari Syndrome in China

  2015cites this paper
• Thrombotic Venous Diseases of the Liver

  2015influential citation
• Associations of Antiphospholipid Antibodies With Splanchnic Vein Thrombosis

  2015cites this paper
• Thrombophilic factor analysis in cirrhotic patients with portal vein thrombosis

  2015cites this paper
• Novel insights into the development of portal vein thrombosis in cirrhosis patients

  2015cites this paper
• Portal vein thrombosis.

  2015cites this paper
• FunMod: A Cytoscape Plugin for Identifying Functional Modules in Undirected Protein–Protein Networks

  2014cites this paper
• Selection of treatment modalities for Budd-Chiari Syndrome in China: a preliminary survey of published literature.

  2014cites this paper
• Identifying Sub-Network Functional Modules in Protein Undirected Networks

  2014cites this paper
• Methylenetetrahydrofolate reductase C677T gene mutation and hyperhomocysteinemia in Budd–Chiari syndrome and portal vein thrombosis: A systematic review and meta‐analysis of observational studies

  2014cites this paper
• JAK2 V617F mutation and 46/1 haplotype in Chinese Budd‐Chiari syndrome patients

  2014cites this paper
• The JAK2 46/1 haplotype (GGCC) in myeloproliferative neoplasms and splanchnic vein thrombosis: a pooled analysis of 26 observational studies

  2014cites this paper
• Prevalence and risk factors of hepatocellular carcinoma in Budd–Chiari syndrome: a systematic review

  2013cites this paper
• Primary extrahepatic portal vein obstruction in adults: A single center experience

  2013cites this paper
• Hepatic Manifestations in Hematological Disorders

  2013cites this paper
• Prevalence of inherited antithrombin, protein C, and protein S deficiencies in portal vein system thrombosis and Budd‐Chiari syndrome: A systematic review and meta‐analysis of observational studies

  2013cites this paper
• [Non-cirrhotic portal hypertension with nearly lethal consequences].

  2013influential citation
• Duplicates in systematic reviews: A critical, but often neglected issue

  2013cites this paper
• Thrombotic risk factors in Chinese Budd-Chiari syndrome patients

  2013cites this paper
• Prevalence of hepatocellular carcinoma in Chinese Budd-Chiari syndrome patients: an extended systematic review using Chinese-language databases.

  2013cites this paper
• Percutaneous recanalization for Budd-Chiari syndrome: an 11-year retrospective study on patency and survival in 177 Chinese patients from a single center.

  2013cites this paper
• Prognostic factors in non-malignant and non-cirrhotic patients with portal cavernoma: an 8-year retrospective single-center study.

  2013cites this paper
• Find Duplicates among the PubMed, EMBASE, and Cochrane Library Databases in Systematic Review

  2013cites this paper
• Familial Budd-Chiari Syndrome in China: A Systematic Review of the Literature

  2013cites this paper
• Prevalence of covert duplicate publications in Budd-Chiari syndrome articles in China: a systematic analysis.

  2013cites this paper
• An update on the diagnosis and management of Budd–Chiari syndrome

  2012cites this paper
• Abdominal thromboses of splanchnic, renal and ovarian veins.

  2012cites this paper
• Prevalence of the JAK2V617F mutation in Chinese patients with Budd‐Chiari syndrome and portal vein thrombosis: A prospective study

  2012cites this paper
• Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.

  2012cites this paper
• Hepatic and Portal Vein Thrombosis : studies on epidemiology and risk factors

  2011influential citation
• Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis.

  2011influential citation